Sera Prognostics (NASDAQ:SERA) Stock Rating Reaffirmed by William Blair

Sera Prognostics (NASDAQ:SERA)‘s stock had its “outperform” rating reaffirmed by investment analysts at William Blair in a research note issued to investors on Friday, RTT News reports.

Sera Prognostics Stock Performance

Shares of SERA stock opened at $9.79 on Friday. The firm has a market capitalization of $317.49 million, a price-to-earnings ratio of -8.44 and a beta of 1.33. The stock’s 50-day simple moving average is $9.69 and its 200-day simple moving average is $6.71. Sera Prognostics has a fifty-two week low of $1.52 and a fifty-two week high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.25) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.25). The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.10 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 45.74%. As a group, equities analysts forecast that Sera Prognostics will post -0.94 earnings per share for the current year.

Insider Transactions at Sera Prognostics

In related news, CEO Zhenya Lindgardt sold 38,899 shares of the company’s stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $9.37, for a total value of $364,483.63. Following the sale, the chief executive officer now owns 908,104 shares in the company, valued at $8,508,934.48. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Sera Prognostics news, CEO Zhenya Lindgardt sold 38,899 shares of Sera Prognostics stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $9.37, for a total transaction of $364,483.63. Following the completion of the transaction, the chief executive officer now owns 908,104 shares in the company, valued at approximately $8,508,934.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Austin Aerts sold 8,092 shares of the company’s stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $9.37, for a total value of $75,822.04. Following the completion of the sale, the chief financial officer now owns 322,488 shares in the company, valued at approximately $3,021,712.56. The disclosure for this sale can be found here. Insiders sold a total of 92,903 shares of company stock worth $866,284 over the last three months. 15.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sera Prognostics

Several large investors have recently made changes to their positions in the company. Perigon Wealth Management LLC acquired a new position in shares of Sera Prognostics in the fourth quarter worth about $509,000. Vanderbilt University purchased a new position in Sera Prognostics during the fourth quarter worth approximately $284,000. Resource Consulting Group Inc. acquired a new stake in Sera Prognostics in the fourth quarter valued at approximately $265,000. CWM LLC purchased a new stake in shares of Sera Prognostics in the fourth quarter valued at approximately $242,000. Finally, Sanders Morris Harris LLC acquired a new position in shares of Sera Prognostics during the 1st quarter worth approximately $174,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.